Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Neuroleptic malignant syndrome].

B Sczesni1, J Schröder, H Becker

  • 1Neurologische Klinik, Ruhr-Universität, Bochum, Bundesrepublik Deutschland.

Wiener Klinische Wochenschrift
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Quality of life in patients with remitting-relapsing multiple sclerosis in Germany].

Der Nervenarzt·2003
Same author

Quality of life as a predictor for change in disability in MS.

Neurology·2001
Same author

Prognostic factors in the management of blunt hepatic injury.

Annali italiani di chirurgia·1992
Same author

Managerial issues associated with program evaluation in schools of nursing.

The Journal of nursing education·1992
Same author

Are CAT-scans necessary for preoperative localization of insulinomas?

The European journal of medicine·1992
Same author

[Liver function tests in a clinical comparison].

Zeitschrift fur Gastroenterologie·1992

Neuroleptic malignant syndrome (NMS) is a severe reaction to dopamine receptor blockade. Early recognition and treatment with standard drugs or intravenous lisuride are crucial for patient outcomes.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurology

Context:

  • Neuroleptic malignant syndrome (NMS) is a rare but life-threatening condition.
  • It is associated with the use of antipsychotic medications that block dopamine receptors.

Purpose:

  • To discuss the clinical features, differential diagnosis, and pathogenesis of NMS.
  • To review therapeutic strategies for managing NMS, including standard drugs and intravenous lisuride.

Summary:

  • NMS is presumed to result from dopamine receptor blockade in the basal ganglia and hypothalamus.
  • Key symptoms include hyperthermia, muscular rigidity, elevated creatine phosphokinase, autonomic dysfunction, and potential consciousness impairment.

Impact:

Related Experiment Videos

  • Provides a comprehensive overview of NMS for clinicians and researchers.
  • Highlights the importance of prompt diagnosis and therapeutic intervention for improved patient prognosis.